ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
COVID vaccines

China builds plants for mRNA vaccines still in development limbo

CanSino, Sinopharm seek Chinese equivalents of Pfizer and Moderna shots

Sinovac Biotech is among the Chinese players that have developed convential vaccines against COVID-19.   © Reuters

SHANGHAI -- Chinese drugmakers are building factories meant to produce mRNA vaccines like the Western ones that have been shown to work against COVID-19. There's one problem: the shots look increasingly likely not to be ready by the time the plants are completed.

CanSino Biologics is due to finish building a factory in Shanghai at the end of November. The biotech startup's project, which has received more than 1 billion yuan ($139 million) in investment, covers a 17,000-sq.-meter site that will house three buildings, according to the local government.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more